technetium (99m tc) fanolesomab
Trade name: Neurospec
mAbwithdrawnImaging agent
Approved
Jul 2, 2004
Technetium (99mTc) fanolesomab is a mouse monoclonal antibody formerly used to aid in the diagnosis of appendicitis. It is labeled with a radioisotope, technetium-99m (99mTc). — Wikipedia
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
2000s
- Jul 2, 2004
Palatin Technologies — Earliest FDA Approval
- Jul 2, 2004
Palatin Technologies — NDA Organization
Indications
Approved for
Mechanism of action
- Selectin EBINDING AGENT
SELE binding agent
- Unspecified targetOTHER
Diagnostic
Approval history
- withdrawnJul 2, 2004
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
- Imaging
- 99-MTC
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaTechnetium (99mTc) fanolesomab ↗
- ChEMBLCHEMBL2109331 ↗
- ChEMBLCHEMBL2107902 ↗
Also known as
- 99mtc-fanolesomab
- 99mtc-labeled anti-cd15 mab
- 99tc-fanolesomab
- anti-ssea-1
- anti-ssea-1
- anti-ssea-1 mab
- fanolesomab
- fanolesomab
- leutech
- leutech
- leutech
- monoclonal antibody anti-ssea-1
- neutrospec
- neutrospec
- rb5-igm
- rb5-igm
- tc-99m anti-ssea-1
- tc-99m anti-ssea-1
- tc-99m rb5-igm
- technetium (99m tc) fanolesomab
- technetium (99mtc) fanolesomab
- technetium (99mtc) fanolesomab
- technetium tc 99m fanolesomab
- technetium tc 99m fanolesomab
Organizations
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Palatin Technologies | For profit | NDA | Jul 2, 2004 |